Business Context and Reporting Period
Company: StemCells, Inc. (Note: Input metadata referenced "Microbot Medical Inc." but the filing text identifies the registrant as StemCells, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2009
Business Overview: A biopharmaceutical company focused on developing and commercializing cell-based technologies, specifically human neural stem cells (HuCNS-SC) for central nervous system disorders and human liver engrafting cells. The company is pre-revenue regarding therapeutic products and relies on external financing, grants, and licensing.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Total Revenue | $322,053 | $47,182 |
| Gross Profit | $262,528 | $47,182 |
| Net Loss | $(16,647,911) | $(13,260,465) |
| Net Loss Per Share (Basic & Diluted) | $(0.17) | $(0.16) |
| Cash and Cash Equivalents (End of Period) | $36,760,470 | $18,592,723 |
| Total Assets | $49,072,168 | $41,230,340 |
| Total Liabilities | $22,424,421 | $19,421,355 |
| Stockholders' Equity | $26,647,747 | $21,808,985 |
Debt and Liquidity: The company holds approximately $36.8 million in cash and cash equivalents. Total debt obligations include capital lease obligations ($191,928) and bond payables ($936,667). A significant liability is the fair value of warrant liability, recorded at $11,092,862.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 583% year-over-year (from $47k to $322k). This was driven primarily by the consolidation of revenues from the acquisition of Stem Cell Sciences Plc (SCS) operations in April 2009, which contributed product sales and grant revenue not present in the prior year.
- Operating Expenses: Total operating expenses increased 5% to $14.6 million. Research and Development (R&D) expenses rose 4% to $9.3 million, largely due to the integration of SCS operations. General and Administrative (G&A) expenses increased 3% to $4.7 million, driven by acquisition costs ($710k) and stock-based compensation, partially offset by reduced legal fees.
- Wind-Down Expenses: Increased 67% to $545,500. This includes a new $310,000 reserve for closing the acquired Australian facility and adjustments to the long-standing Rhode Island facility reserve.
- Other Income/Expense: Net other expense was $2.3 million compared to net other income of $535k in the prior year. This shift was primarily due to a $2.65 million loss from the change in fair value of the warrant liability, partially offset by a $398k gain on the sale of marketable securities (ReNeuron shares).
- Cash Flow: Net cash used in operating activities was $12.4 million. Net cash provided by financing activities surged to $15.2 million, primarily from the sale of common stock ($15.0 million net proceeds).
Guidance, Outlook, and Risks
- Acquisition Impact: The April 1, 2009 acquisition of SCS operations added proprietary cell technologies (embryonic, iPS, and adult stem cells) and a media formulation business. The company expects these assets to support nearer-term commercial opportunities in research tools.
- Clinical Progress: The company completed a Phase I clinical trial of HuCNS-SC cells for Batten disease (NCL) in January 2009, reporting the cells were well-tolerated with evidence of engraftment. A Phase I trial for Pelizaeus-Merzbacher Disease (PMD) is expected to begin enrolling in 2009.
- Liquidity Outlook: Management states the company has incurred significant operating losses since inception and expects to incur additional losses in the foreseeable future. Continued operations depend on obtaining significant additional capital through equity/debt offerings, grants, or collaborations. As of August 3, 2009, approximately $61 million remained available under a universal shelf registration statement.
- Legal Contingencies: Ongoing patent infringement litigation against Neuralstem, Inc. regarding six patents. The PTO upheld the validity of all six patents in 2008 and 2009. The company has agreed to indemnify NeuroSpheres for litigation costs, which may be offset against future royalty payments.
- Wind-Down Risks: Significant uncertainty remains regarding the exit costs for the Rhode Island facility (lease expires 2013) and the recently acquired Australian facility. Reserves are subject to adjustment based on vacancy rates and market conditions.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $36.8 million cash balance against projected R&D and operating burn rates, given the expectation of continued losses.
- Warrant Liability Volatility: Monitor the fair value of the $11.1 million warrant liability, as fluctuations in stock price and volatility will directly impact reported net income/loss.
- SCS Integration: Assess the progress of integrating SCS operations and the realization of revenue from the acquired media and reagent business.
- Facility Exit Costs: Review quarterly updates on the Rhode Island and Australia wind-down reserves, as changes in vacancy assumptions can materially affect expenses.
- Equity Dilution: Track future equity issuances under the shelf registration and sales agreements with Cantor Fitzgerald, as the company relies heavily on equity financing.